Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T- Cell Lymphoma

被引：3

作者：

Fukuhara, Noriko ^{[1
]}

Kim, Won Seog ^{[2
]}

Yoon, Dok Hyun ^{[3
]}

Negoro, Eiju ^{[4
]}

Yamamoto, Kazuhito ^{[5
]}

Uchida, Toshiki ^{[6
]}

Izutsu, Koji ^{[7
]}

Terui, Yasuhito ^{[8
,9
]}

Nakajima, Hideaki ^{[10
]}

Ando, Kiyoshi ^{[11
]}

Suehiro, Youko ^{[12
]}

Kang, Hye Jin ^{[13
]}

Ko, Po-Shen ^{[14
]}

Nagahama, Fumiko ^{[15
]}

Sonehara, Yusuke ^{[15
]}

Nagai, Hirokazu ^{[16
]}

Tien, Hwei-Fang ^{[17
]}

Kwong, Yok-Lam ^{[18
]}

Tobinai, Kensei ^{[19
]}

机构：

[1] Tohoku Univ Hosp, Dept Hematol, Sendai, Miyagi, Japan

[2] Samsung Med Ctr, Dept Med, Hematol & Oncol, Seoul, South Korea

[3] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[4] Univ Fukui Hosp, Dept Hematol & Oncol, Fukui, Japan

[5] Aichi Canc Ctr Hosp, Dept Hematol & Cell Therapy, Nagoya, Aichi, Japan

[6] Nagoya Daini Hosp, Japanese Red Cross Aichi Med Ctr, Dept Hematol & Oncol, Nagoya, Aichi, Japan

[7] Natl Canc Ctr, Dept Hematol, Tokyo, Japan

[8] Canc Inst Hosp Japanese Fdn Canc Res, Dept Hematol Oncol, Tokyo, Japan

[9] Saitama Med Univ Hosp, Dept Hematol, Saitama, Japan

[10] Yokohama City Univ Med, Dept Hematol Rheumatol Infect Dis, Yokohama, Kanagawa, Japan

[11] Tokai Univ Hosp, Dept Hematol & Oncol, Isehara, Kanagawa, Japan

[12] Natl Hosp Org, Dept Hematol, Kyushu Canc Ctr, Fukuoka, Japan

[13] Korea Canc Ctr Hosp, Seoul, South Korea

[14] Taipei Vet Gen Hosp, Div Hematol, Dept Med, Taipei, Taiwan

[15] Solasia Pharma K K, Tokyo, Japan

[16] Natl Hosp Org, Clin Res Ctr, Nagoya Med Ctr, Nagoya, Aichi, Japan

[17] Natl Taiwan Univ Hosp, Div Hematol, Dept Internal Med, Taipei, Taiwan

[18] Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China

[19] Natl Canc Ctr, Tokyo, Japan

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-145512

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1376

引用

页数：5

共 50 条

[21] Pembrolizumab in Relapsed/Refractory Extranodal NK/T Cell Lymphoma and Mature T Cell Lymphoma: A Prospective Phase II Study
Chan, Thomas
Tse, Eric
BLOOD, 2023, 142
[22] Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
O'Connor, Owen A.
Horwitz, Steven
Masszi, Tamas
Van Hoof, Achiel
Brown, Peter
Doorduijn, Jeannette
Hess, Georg
Jurczak, Wojciech
Knoblauch, Poul
Chawla, Shanta
Bhat, Gajanan
Choi, Mi Rim
Walewski, Jan
Savage, Kerry
Foss, Francine
Allen, Lee F.
Shustov, Andrei
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (23) : 2492 - U21
[23] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Fisher, Richard I.
Bernstein, Steven H.
Kahl, Brad S.
Djulbegovic, Benjamin
Robertson, Michael J.
de Vos, Sven
Epner, Elliot
Krishnan, Amrita
Leonard, John P.
Lonial, Sagar
Stadtmauer, Edward A.
O'Connor, Owen A.
Shi, Hongliang
Boral, Anthony L.
Goy, Andre
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4867 - 4874
[24] INTERIM RESULTS OF A PHASE II STUDY OF FONDAZIONE ITALIANA LINFOMI ON GEMCITABINE PLUS ROMIDEPSIN IN RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA PATIENTS
Pellegrini, C.
Broccoli, A.
Casadei, B.
Chiappella, A.
Corradini, P.
Derenzini, E.
Dodero, A.
Farina, L.
Gandolfi, L.
Ladetto, M.
Monaco, F.
Orsucci, L.
Quirini, F.
Salvi, F.
Spina, F.
Stefoni, V.
Tonialini, L.
Vitolo, U.
Argnani, L.
Cavo, M.
Zinzani, P. L.
HAEMATOLOGICA, 2015, 100 : 18 - 19
[25] A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
Cinzia Pellegrini
Anna Dodero
Annalisa Chiappella
Federico Monaco
Debora Degl’Innocenti
Flavia Salvi
Umberto Vitolo
Lisa Argnani
Paolo Corradini
Pier Luigi Zinzani
Journal of Hematology & Oncology, 9
[26] A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
Pellegrini, Cinzia
Dodero, Anna
Chiappella, Annalisa
Monaco, Federico
Degl'Innocenti, Debora
Salvi, Flavia
Vitolo, Umberto
Argnani, Lisa
Corradini, Paolo
Zinzani, Pier Luigi
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
[27] A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma
Foss, Francine
Advani, Ranjana
Duvic, Madeleine
Hymes, Kenneth B.
Intragumtornchai, Tanin
Lekhakula, Arnuparp
Shpilberg, Ofer
Lerner, Adam
Belt, Robert J.
Jacobsen, Eric D.
Laurent, Guy
Ben-Yehuda, Dina
Beylot-Barry, Marie
Hillen, Uwe
Knoblauch, Poul
Bhat, Gajanan
Chawla, Shanta
Allen, Lee F.
Pohlman, Brad
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (06) : 811 - 819
[28] Pralatrexate: Phase 1/2 Study in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)
Maeda, Yoshinobu
Tobinai, Kensei
Nagai, Hirokazu
Nakane, Takahiko
Shimoyama, Tatsu
Nakazato, Tomonori
Sakai, Rika
Ishikawa, Takayuki
Izutsu, Koji
Ueda, Ryuzo
BLOOD, 2016, 128 (22)
[29] Two Phase I and Pharmacokinetic Studies of Darinaparsin (Organic Arsenic Compound) in Japanese and Korean Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)
Kim, Won-Seog
Ogura, Michinori
Uchida, Toshiki
Uike, Naokuni
Abe, Yasunobu
Ishizawa, Kenichi
Okitsu, Yoko
Tobinai, Kensei
Nagahama, Fumiko
Sonehara, Yusuke
Nagai, Hirokazu
BLOOD, 2015, 126 (23)
[30] Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma
Zekri, JM
Hough, RE
Davies, JM
Molife, R
Hancock, BW
Lorigan, PC
BRITISH JOURNAL OF CANCER, 2003, 88 (09) : 1335 - 1338

← 1 2 3 4 5 →